{"title":"间充质干细胞治疗类固醇难治性急性移植物抗宿主病的研究进展","authors":"Minmin Liang, Xiaobo Ni, Yan Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.011","DOIUrl":null,"url":null,"abstract":"Currently, steroid refractory acute graft versus host disease (SR-aGVHD) is one of severe complications in patients with hematological diseases who accept allogeneic hematopoietic stem cell transplantation (allo-HSCT). Glucocorticoids are first-line treatments for acute graft versus host disease (aGVHD), whereas 25%-30% of patients with aGVHD are ineffective to these drugs, which usually have a poor prognosis. The 2-year overall survival (OS) rate is about 10% or even lower of these patients. Mesenchymal stem cell (MSC), pluripotent progenitor cell with extensive immunomodulatory capacity, is thought to induce immunosuppression and delay the inflammatory state triggered by SR-aGVHD. Recent studies have confirmed that intravenous infusion of MSC is feasible and effective in the treatment of SR-aGVHD, and has gradually become a hot topic. In order to widely apply MSC in the treatment of SR-aGVHD, this article intends to summarize the biological characteristics, the mechanism of treatment in patients with SR-aGVHD and the progress of clinical application of MSC. \n \n \nKey words: \nGraft vs host disease; Mesenchymal stem cells; Immunoregulatory; Cell adhesion molecules; Steroid refractory acute graft versus host disease; Indoleamine 2, 3-dioxygenase","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"238-243"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress of mesenchymal stem cell in treatment of steroid refractory acute graft versus host disease\",\"authors\":\"Minmin Liang, Xiaobo Ni, Yan Wang\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.03.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Currently, steroid refractory acute graft versus host disease (SR-aGVHD) is one of severe complications in patients with hematological diseases who accept allogeneic hematopoietic stem cell transplantation (allo-HSCT). Glucocorticoids are first-line treatments for acute graft versus host disease (aGVHD), whereas 25%-30% of patients with aGVHD are ineffective to these drugs, which usually have a poor prognosis. The 2-year overall survival (OS) rate is about 10% or even lower of these patients. Mesenchymal stem cell (MSC), pluripotent progenitor cell with extensive immunomodulatory capacity, is thought to induce immunosuppression and delay the inflammatory state triggered by SR-aGVHD. Recent studies have confirmed that intravenous infusion of MSC is feasible and effective in the treatment of SR-aGVHD, and has gradually become a hot topic. In order to widely apply MSC in the treatment of SR-aGVHD, this article intends to summarize the biological characteristics, the mechanism of treatment in patients with SR-aGVHD and the progress of clinical application of MSC. \\n \\n \\nKey words: \\nGraft vs host disease; Mesenchymal stem cells; Immunoregulatory; Cell adhesion molecules; Steroid refractory acute graft versus host disease; Indoleamine 2, 3-dioxygenase\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"238-243\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Research progress of mesenchymal stem cell in treatment of steroid refractory acute graft versus host disease
Currently, steroid refractory acute graft versus host disease (SR-aGVHD) is one of severe complications in patients with hematological diseases who accept allogeneic hematopoietic stem cell transplantation (allo-HSCT). Glucocorticoids are first-line treatments for acute graft versus host disease (aGVHD), whereas 25%-30% of patients with aGVHD are ineffective to these drugs, which usually have a poor prognosis. The 2-year overall survival (OS) rate is about 10% or even lower of these patients. Mesenchymal stem cell (MSC), pluripotent progenitor cell with extensive immunomodulatory capacity, is thought to induce immunosuppression and delay the inflammatory state triggered by SR-aGVHD. Recent studies have confirmed that intravenous infusion of MSC is feasible and effective in the treatment of SR-aGVHD, and has gradually become a hot topic. In order to widely apply MSC in the treatment of SR-aGVHD, this article intends to summarize the biological characteristics, the mechanism of treatment in patients with SR-aGVHD and the progress of clinical application of MSC.
Key words:
Graft vs host disease; Mesenchymal stem cells; Immunoregulatory; Cell adhesion molecules; Steroid refractory acute graft versus host disease; Indoleamine 2, 3-dioxygenase
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
